1. Home
  2. HQH vs EVO Comparison

HQH vs EVO Comparison

Compare HQH & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Healthcare Investors Shares of Beneficial Interest

HQH

abrdn Healthcare Investors Shares of Beneficial Interest

HOLD

Current Price

$17.51

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$2.43

Market Cap

895.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HQH
EVO
Founded
1986
1993
Country
United States
Germany
Employees
N/A
4766
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
895.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HQH
EVO
Price
$17.51
$2.43
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
155.8K
108.8K
Earning Date
01-01-0001
05-05-2026
Dividend Yield
11.56%
N/A
EPS Growth
N/A
N/A
EPS
1.09
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7.13
P/E Ratio
$16.62
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.77
$2.31
52 Week High
$20.46
$4.80

Technical Indicators

Market Signals
Indicator
HQH
EVO
Relative Strength Index (RSI) 35.88 34.47
Support Level $16.23 $2.31
Resistance Level $19.57 $3.78
Average True Range (ATR) 0.43 0.08
MACD -0.01 0.01
Stochastic Oscillator 4.35 25.54

Price Performance

Historical Comparison
HQH
EVO

About HQH abrdn Healthcare Investors Shares of Beneficial Interest

abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: